Tag Archives: BIOTECH STOCKS

Biotech Stocks Hit Record Highs…Again

BIOtech-stocks

Biotech stocks hit an all-time high this week, driven by strong performance among large cap sector leaders with strong product portfolios. A common benchmark for the sector, the NASDAQ Biotechnology Index (NBI) has outperformed the S&P 500 by a factor of over 2X. The NBI is up 61% year to date, compared with 26% for the S&P 500. We’ll be discussing this strong performance in New York this February at the BIO CEO & Investor Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Word on the Street – Biotech Stocks Only Have Room to Go Up

The Opening Lunch Plenary at this year’s BIO CEO & Investor Conference was a lively discussion between portfolio managers and senior buy-side analysts looking to forecast the year ahead in biotech. BIO’s own, Celia Economides, Director, Investor Relations & Programs, reminded us all where we were 15 years ago at the inception of this event. At the 1999 event, there were 18 presenting companies, zero 1X1 meetings scheduled and 271 attendees.  As of day one, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Recommended Reading from BIOtechNOW

Partnering Meetings

We hope the dust has settled from Boston’s International Convention, and you’re ready for a busy fall schedule! Here’s just a quick post on some recent articles that have been published on BIOtechNOW that’s worth a read. 2012 Fall Event Preview – A recap of BIO’s upcoming BD events, among others. 2012 BIO Convention in China: Highlighting Cross-Border Partnering in Biotechnology – Take a deeper look at the 2nd Annual BIO China event. We’re also Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Indices, IPOs, and New Drug Approvals – Update July 6th 2012

Index-Perfomance-June-2012-thumb

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued on its path of outperforming the market, up 24.6 percent and increasing its Year-to-Date (YTD) lead over the S&P 500 which is up 8.3 percent. The Amex Biotech Index (BTK) closed out June up a hefty 34.6 percent YTD: 2. IPOs: Tesaro, Inc. (TSRO) was June’s sole U.S. IPO, raising $81M.  The company was formed just two years ago and has aggressively in-licensed cancer treatments from Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Biotech IPO Update for May 18th, 2011

There are now eight biotech IPOs for 2011, bringing the total for the recent US IPO window to 28. Post-IPO performance is finally picking up with the median return at +14% for these 28 IPOs. Advanced BioHealing was scheduled to IPO this week, but Shire (SHGPY) came in with a $750M offer to buy the company. Sagent Pharmaceuticals (SGNT) was the most recent IPO, back in April. Sagent is a specialty pharma company selling injectable Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,